APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer

Groskopf J, Aubin SMJ, Deras IL, Blase A, Bodrug S, Clark C, Brentano S, Mathis J, Pham J, Meyer T, Cass M, Hodge P, Macairan ML, Marks LS, Rittenhouse H.
Clin Chem 2006;52:1089-95.

• This paper describes the characterisation of a prototype quantitative PCA3-based (PROGENSA^TM) test for whole urine.
• It also shows that in 68 males undergoing their first/initial biopsy, the PCA3 Score was able to significantly differentiate between (Figure)

• healthy normal men
• men with a negative biopsy (including 40 men with BPH and/or inflammation) and
• men with a positive biopsy.

Reviewed by

Prof. J. Schalken, Prof. B. Tombal, Prof. H. Van Poppel

More information: http://www.ncbi.nlm.nih.gov/